NFKB1 and inflammatory bowel disease: GAR-PLGA-ES100 NPs were designed to load and deliver the drug for targeted delivery to the colon to treat IBD and inhibit inflammation by reducing NF-κB, proinflammatory cytokine TNF-α and chemokine interleukin (IL)-8 in CACO-2 cells.